Eli Lilly's animal health division Elancorecently filed for a US offering that should come in the fall, raising as much as $3 billion in what may be the year's biggest IPO. Elanco mainly competes with three other giant global animal health companies....read more
Following a seasonally calm start to the year, global IPO issuance improved in the second quarter of 2015. Quarterly proceeds increased 29% from the first quarter to $46.6 billion, but still remained down 24% from last year’s levels. IPO proceeds in the...read more
The Renaissance IPO Index (Ticker: IPOUSA), the underlying index for the Renaissance IPO ETF (Ticker: IPO), will implement the following constituent changes at the market’s close on Friday, March 20, 2015:
Additions:
Juno Therapeutics
Shell Midstream ...read more
Nexvet, which is developing biologics for the treatment of pain and inflammation in cats and dogs, announced terms for its IPO on Monday. The Dublin, Ireland-based company plans to raise $58 million by offering 4.0 million shares at a price range of $13 to $16. ...read more
Eli Lilly's Elanco may be 2018's biggest IPO
Eli Lilly's animal health division Elanco recently filed for a US offering that should come in the fall, raising as much as $3 billion in what may be the year's biggest IPO. Elanco mainly competes with three other giant global animal health companies....read more
Renaissance Capital's 2Q 2015 Global IPO Quarterly Review
Following a seasonally calm start to the year, global IPO issuance improved in the second quarter of 2015. Quarterly proceeds increased 29% from the first quarter to $46.6 billion, but still remained down 24% from last year’s levels. IPO proceeds in the...read more
Renaissance IPO Index - Notice of March 2015 Quarterly Changes
The Renaissance IPO Index (Ticker: IPOUSA), the underlying index for the Renaissance IPO ETF (Ticker: IPO), will implement the following constituent changes at the market’s close on Friday, March 20, 2015: Additions: Juno Therapeutics Shell Midstream ...read more
Paining cats and dogs: Nexvet sets terms for $58 million IPO
Nexvet, which is developing biologics for the treatment of pain and inflammation in cats and dogs, announced terms for its IPO on Monday. The Dublin, Ireland-based company plans to raise $58 million by offering 4.0 million shares at a price range of $13 to $16. ...read more